We effectively and efficiently translate groundbreaking science into medical innovation for people with cancer. We received our first U.S. FDA approval in 2019.
We effectively and efficiently translate groundbreaking science into medical innovation for people with cancer. We received our first U.S. FDA approval in 2019.